Literature DB >> 22349206

Acetabular reconstruction using morselized allograft and a reinforcement ring for revision arthroplasty with Paprosky type II and III bone loss: survival analysis of 95 hips after 5 to 13 years.

R Philippe1, O Gosselin, J Sedaghatian, C Dezaly, O Roche, F Sirveaux, D Molé.   

Abstract

INTRODUCTION: Treatment of acetabular loosening and accompanying bone defects requires that the bone stock be rebuilt, the primary stability ensured, and the hip center of rotation restored to its anatomical location. HYPOTHESIS: Acetabular reconstruction using morselized allograft and a reinforcement ring will meet these requirements and ensure medium-term survival. PATIENTS AND METHODS: A retrospective study was performed on 95 acetabular revision cases (95 patients) performed between 1987 and 1995. The average age at revision was 69.5 years (42 to 86 years). Among these acetabular loosening cases, 12 cases had a type II Paprosky acetabular bone defect and 83 cases had a type III defect.
RESULTS: The average follow-up was 8 years (5 to 13 years). There were seven post-operative dislocations, three deep infections, and two cases of repeated acetabular loosening. The cumulative survival rate at 14 years was 77.9% (95% CI: 61.96% to 93.84%). The average Postel Merle d'Aubigné (PMA) score improved from 8 (range 6-11) preoperatively to 14.8 (range 8-18) at follow-up; the Harris score improved from 35.3 (range 11-52) to 71.1 (range 40-94) (P<0.001). Based on the parameters outlined by Ranawat, the optimal centre of rotation was restored in 45% of cases. Graft integration was found to be good in 60% of cases. The reinforcement ring had migrated in five cases, including two cases of acetabular loosening that required an additional revision. The functional result was better when the hip center of rotation was restored (P<0.05). Conversely, the position of the hip center of rotation had no effect on graft integration or acetabular fixation. DISCUSSION: This series confirmed that acetabular reconstruction using morselized allograft and a reinforcement ring is effective in the medium term as a treatment for acetabular loosening with severe bone deficiency. It also revealed that restoring the hip center of rotation can improve functional results. LEVEL OF EVIDENCE: Level IV, retrospective study.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22349206     DOI: 10.1016/j.otsr.2011.11.003

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  5 in total

1.  CORR Insights®: Novel Acetabular Cup for Revision THA Improves Hip Center of Rotation: A Radiographic Evaluation.

Authors:  James A Keeney
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

2.  Trabecular titanium cups in acetabular revision arthroplasty: analysis of 10-year survivorship, restoration of center of rotation and osteointegration.

Authors:  Andrea Cozzi Lepri; Matteo Innocenti; Alberto Galeotti; Christian Carulli; Marco Villano; Roberto Civinini
Journal:  Arch Orthop Trauma Surg       Date:  2021-11-15       Impact factor: 2.928

3.  Clinical and Radiological Outcome of Acetabular Reconstruction Rings in Complex Primary and Revision Total Hip Arthroplasty.

Authors:  Natesan Rajkumar; Dhanasekaran Soundarrajan; Panda Chandan Kumar; Palanisami Dhanasekararaja; Shanmuganathan Rajasekaran
Journal:  Indian J Orthop       Date:  2021-06-11       Impact factor: 1.033

4.  Acetabular reconstruction with a reinforcement device and bone grafting in revision arthroplasty-a mean five years of follow-up.

Authors:  Ancuța Zazgyva; Sándor-György Zuh; Ciprian Oliviu Roman; István Gergely; Tudor Sorin Pop
Journal:  Int Orthop       Date:  2015-11-07       Impact factor: 3.075

5.  Clinical and radiological evaluation of post total hip arthroplasty patients with acetabulum defect.

Authors:  Mohammad Zaim Chilmi; Yesa Adietra Suwandani; Dwikora Novembri Utomo; Jeffry Andrianus
Journal:  J Clin Orthop Trauma       Date:  2018-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.